Literature DB >> 12759167

Altered glutamate uptake in peripheral tissues from Down syndrome patients.

Barbara Begni1, Laura Brighina, Lorenzo Fumagalli, Simona Andreoni, Enrico Castelli, Claudia Francesconi, Roberto Del Bo, Nereo Bresolin, Carlo Ferrarese.   

Abstract

Overexpression of APP and SOD induces beta-amyloid deposition and oxidative stress in Down syndrome (DS) patients. Both phenomena may impair glutamate transport and decreased glutamate uptake sites have been demonstrated in patient brains at autopsy. Since alterations of APP metabolism and oxidative damage are systemic, we investigated glutamate uptake in platelets and fibroblasts from DS patients to explore whether abnormalities in this process are inherent properties of DS cells and not secondary to neurodegeneration. Glutamate uptake was significantly decreased in platelets (P<0.005 vs. control) and fibroblasts (P<0.001 vs. control) from DS patients, particularly in those with free trisomy and with mitochondrial point mutations. Systemic impairment of glutamate uptake in DS is suggested, probably related to APP overexpression and mitochondrial dysfunction. Such mechanisms may contribute to neurodegeneration and dementia development in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759167     DOI: 10.1016/s0304-3940(03)00260-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Cellular changes underlying hyperoxia-induced delay of white matter development.

Authors:  Thomas Schmitz; Jonathan Ritter; Susanne Mueller; Ursula Felderhoff-Mueser; Li-Jin Chew; Vittorio Gallo
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

2.  Plasma amino acids and neopterin in healthy persons with Down's syndrome.

Authors:  A W Coppus; D Fekkes; W M A Verhoeven; S Tuinier; J I M Egger; C M van Duijn
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

3.  Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy ((1)H MRS).

Authors:  Giles My Tan; Felix Beacher; Eileen Daly; Jamie Horder; Verinder Prasher; Maria-Luisa Hanney; Robin Morris; Simon Lovestone; Kieran C Murphy; Andrew Simmons; Declan Gm Murphy
Journal:  J Neurodev Disord       Date:  2014-11-27       Impact factor: 4.025

4.  Application of the amniotic fluid metabolome to the study of fetal malformations, using Down syndrome as a specific model.

Authors:  Jun Huang; Jinhua Mo; Guili Zhao; Qiyin Lin; Guanhui Wei; Weinan Deng; Dunjin Chen; Bolan Yu
Journal:  Mol Med Rep       Date:  2017-09-18       Impact factor: 2.952

Review 5.  Rethinking Intellectual Disability from Neuro- to Astro-Pathology.

Authors:  Álvaro Fernández-Blanco; Mara Dierssen
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.